Project Grant R01NS134724
Award Date
9/20/24
Completion Date
8/31/29
Dollars Obligated
$574K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This $502,588 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) aims to develop small molecule inhibitors targeting the CHI3L1/GAL-3 interaction for the treatment of glioblastoma, an aggressive form of brain cancer. The award supports optimization of lead compounds, in vitro and in vivo pharmacokinetic evaluation, and assessment of therapeutic...
This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to develop a novel oncolytic viral therapy for glioblastoma (GBM), the most lethal and frequent primary adult brain tumor. The $563,850 award to the Augusta University Research Institute, Inc. will fund research to create an oncolytic virus that can show improved...
This Project Grant award of $699,125 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will support research to investigate the potential of targeting the enzyme 2-oxoglutarate dehydrogenase (OGDH) as a novel therapy for glioblastoma, the most common and deadly form of brain cancer. The research will build on the grantee's prior findings that OGDH is a critical driver of...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $954,000 to the University of Pittsburgh to conduct research aimed at understanding how aging promotes the growth of glioblastoma, an aggressive form of brain cancer. The project will leverage insights from aging in the nervous system and the molecular circuitry of cancer stem cells to investigate how aging reprograms the tumor immune microenvironment and cell autonomous nuclear...
This $416,265 federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to investigate how low-grade glioma infiltration influences cortical structure and function. The key objectives are to determine how glioma affects inhibitory GABAergic inputs and neuronal population responses in sensory and speech processing...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $633,656 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to Brigham & Women's Hospital in Boston, MA. The grant supports research aimed at improving interleukin-12 (IL-12) immunogene therapy for treating glioblastoma, an aggressive brain cancer. Specifically, the research will: 1) Compare the efficacy, tolerability, and immune effects of administering...
This $732,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support research under the Cancer Treatment Research program. The grant recipient, Northwestern University, will develop a bridge-lipid nanoparticle platform to reprogram immunosuppressive tumor-associated myeloid cells and potentiate radiotherapy for glioblastoma. Over a five-year period, the university will conduct three aims: harnessing myeloid cells to phagocytose...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $682,596 to The University of Texas Southwestern Medical Center to study the metabolic mechanisms driving the progression of high-grade gliomas, a deadly type of brain cancer. The research aims to better understand how aberrant metabolite secretion by glioma cells impacts communication with surrounding neurons and contributes to tumor growth. This 5-year project will...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $547,687 to develop small molecule inhibitors of the SLIT2/ROBO signaling pathway as novel therapeutics for treating glioblastoma (GBM), an aggressive form of brain cancer. The grant aims to screen a chemical library for SLIT2 binding compounds, validate the top hits as SLIT2/ROBO inhibitors, and perform initial medicinal chemistry optimization. This work is expected to...
This Project Grant award of $649,226, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research conducted by the University of California, San Diego (UCSD) to investigate mechanisms of therapeutic resistance in glioblastoma (GBM), a highly aggressive brain cancer.
The key objectives of this 4-year project are to: 1) elucidate the upstream...